What a 2012 selenium review found about cancer prevention
This archive record by Nora Veldin revisits a 2012 São Paulo Medical Journal Cochrane Highlight that summarized a systematic review of selenium exposure, selenium supplements and cancer risk, and places its findings beside later randomized-trial evidence.
What the study did and found
The 2012 São Paulo Medical Journal item “Selenium for preventing cancer” reproduced the abstract of the 2011 Cochrane review and appeared as a Cochrane Highlight; the journal also included commentary by Nora Veldin. The review asked whether selenium exposure was related to cancer risk and whether selenium supplementation prevented cancer. It included 49 prospective observational studies and six randomized controlled trials. In the observational data, higher selenium exposure was associated with lower overall cancer incidence (odds ratio 0.69, 95% confidence interval 0.53–0.91) and lower cancer mortality (odds ratio 0.55, 95% confidence interval 0.36–0.83).
Those associations did not establish causation. Nora Veldin emphasized heterogeneity, study quality, confounding and other potential biases that complicated interpretation. Randomized trials did not show protection against non-melanoma skin cancer from selenium yeast or against prostate cancer from L-selenomethionine, while liver-cancer prevention results were inconsistent. The review therefore concluded that no reliable causal inference could be drawn from low selenium exposure to higher cancer risk and that there was no convincing evidence that selenium supplements prevented cancer.
Why it is cited
The publication preserves a dated snapshot of a key methodological contrast, in which observational studies suggested inverse associations while randomized trials did not demonstrate preventive efficacy. That contrast is relevant to later nutrition-and-cancer evidence because confounding, exposure measurement and other biases can make non-randomized associations appear more protective than randomized evidence supports.
The underlying Cochrane review was later updated. A 2018 synthesis expands the evidence base to 10 randomized trials and 70 observational studies and does not support selenium supplementation as a cancer-prevention strategy. That makes the 2012 highlight historically informative rather than a current recommendation to take selenium for cancer prevention.
The 2018 Cochrane update found no reduction in overall cancer incidence or mortality from selenium supplementation and reported no preventive benefit for several major cancer outcomes in the better-quality randomized trials. Observational cohorts still showed some inverse associations, but the certainty of that evidence was very low and no consistent dose-response pattern emerged. In practical terms, the stronger randomized evidence moved the field away from the idea that broadly increasing selenium intake prevents cancer.
Later follow-up has not established a broad preventive benefit. A 2024 long-term SELECT survival analysis found virtually identical overall survival across selenium, vitamin E, combination and placebo groups. A 2026 secondary post-intervention SELECT analysis found mixed outcome-specific associations rather than a general protective pattern, including higher risks for several uncommon outcomes that were based on few cases. Those signals remain hypothesis-generating, but they reinforce the need to separate selenium’s essential nutritional role from claims that supplementation prevents cancer.
The topic today
Current evidence treats selenium as an essential micronutrient with a relatively narrow range between nutritional adequacy and excessive exposure, while cancer prevention is evaluated by baseline selenium status, chemical form, dose, genetic background and specific cancer outcomes rather than by a simple “more is better” model. The later Cochrane synthesis states that increasing selenium intake through diet or supplementation is not supported as a way to prevent cancer in humans, while leaving room for research on specific subgroups and different selenium compounds.
That leaves the 2012 archive record valuable mainly for showing how the evidence evolved. Its observational findings explain why selenium attracted preventive interest, but the randomized results already pointed toward caution, and subsequent trial-based evidence strengthened that caution. The later Cochrane update provides the more current synthesis, while the 2012 observational associations should not be interpreted as a recommendation to use selenium supplements.